LATIB 400mg capsules medication leaflet

L01EA01 imatinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | BCR-ABL tyrosine kinase inhibitors

Imatinib is a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia (CML) and other cancers, such as gastrointestinal stromal tumors (GIST). It works by blocking the activity of abnormal proteins that drive cancer cell growth.

The medication is taken orally, usually once daily, as directed by a doctor. It is important to follow the recommended dose to maximize treatment effectiveness.

Side effects may include nausea, vomiting, fluid retention, muscle pain, or fatigue. In rare cases, severe allergic reactions or liver failure may occur.

Imatinib is not recommended for patients with hypersensitivity to this medication or severe liver impairment.

General data about LATIB 400mg

Substance: imatinib

Date of last drug list: 01-05-2018

Commercial code: W64186003

Concentration: 400mg

Pharmaceutical form: capsules

Quantity: 90

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PABIANICKIE ZAKLADY FARMACEUTYCZNE POLFA S.A. - POLONIA

Holder: EGIS PHARMACEUTICALS PLC - UNGARIA

Number: 13981/2021/01

Shelf life: 30 months

Pharmaceutical forms available for imatinib

Concentrations available for imatinib

100mg, 300mg, 400mg, 50mg